Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline 4Q

Vaccine sales were up 85% to $2.4 billion with flu pre-pandemic sales accounting for $1.3 billion in the quarter.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 4Q

4Q Revenues: $13.0 billion (+18%)

4Q Earnings: $2.7 billion (+80%)

FY Revenues: $44.3 billion (-2%)

FY Earnings: $8.8 billion (+1%)

Comments: Vaccine sales were up 85% to $2.4 billion with flu pre-pandemic sales accounting for $1.3 billion in the quarter. Seretide/Advair sales were $2.2 billion (+10%). Relenza sales were $408 million, up from $19 million in 4Q08. Valtrex sales were down 38% to $368 million. Seroxat/Paxil sales were $225 million (-10%). Avodart sales were $231 million (+19%). Avandia product sales were $310 million (-15%). R&D expenses in the quarter were $1.8 billion (+2%). The company announced an expansion of its restructuring efforts, and will phase out R&D in several therapeutic areas. No numbers were given, but early reports contend that as many as 4,000 R&D staff will be laid off from this new round of cuts.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters